<h3>享受 TipRanks Premium 50% 折扣，放心投资</h3>
<ul>
<li>解锁对冲基金级别的数据和强大的投资工具，帮助您做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，使您的投资组合始终处于最大潜力的状态</li>
</ul>
<p>CARsgen Therapeutics Holdings Ltd. ( (HK:2171) ) 发布了最新动态。</p>
<p>CARsgen Therapeutics 已将现有股票回购计划的期限延长至下次年度股东大会结束，之前已根据 2025 年回购授权回购了 7,627,000 股。此次回购由非 IPO 来源（如业务发展和利息收入）资助，董事会将此举视为公司股价低估其长期增长前景的信号，并作为提升股东价值的措施。此外，主要股东 YIJIE Biotech Holding Limited 及其一致行动人已将其持股比例提高至约 38.2%（不包括库藏股），董事会将此发展解读为市场对 CARsgen 长期投资吸引力的进一步信心，尽管未来的回购仍然是自主决定，并受市场条件的影响。</p>
<p>关于 (HK:2171) 股票的最新分析师评级为卖出，目标价为 HK$14.92。要查看 CARsgen Therapeutics Holdings Ltd. 股票的完整分析师预测列表，请参见 HK:2171 股票预测页面。</p>
<p><strong>关于 CARsgen Therapeutics Holdings Ltd. 的更多信息</strong></p>
<p>CARsgen Therapeutics Holdings Limited 是一家生物技术公司，专注于开发创新的细胞疗法，特别是针对癌症的 CAR-T 治疗。该公司在香港证券交易所上市，通过子公司和关联实体运营，针对国内和全球肿瘤市场提供先进的免疫疗法产品。</p>
<p><strong>平均交易量：</strong> 1,968,220</p>
<p><strong>技术情绪信号：</strong> 卖出</p>
<p><strong>当前市值：</strong> HK$8.6B</p>
<p>在 TipRanks 的股票分析页面上查找关于 2171 股票的详细分析。</p>

科济药业-B

<p>CARsgen Therapeutics Holdings Ltd. 已将其股票回购计划延长至下次年度股东大会，已回购 7,627,000 股。此次回购资金来源于非首次公开募股的渠道，旨在提升股东价值，表明公司认为其股票被低估。此外，YIJIE Biotech Holding Limited 已将其持股比例增加至 38.2%，反映出市场对 CARsgen 长期前景的信心。最新的分析师评级为 “卖出”，目标价格为 14.92 港元</p>

<h3>Claim 50% Off TipRanks Premium and Invest with Confidence</h3>
<div class="lb-trans"><h3>享受 TipRanks Premium 50% 折扣，放心投资</h3>
</div><ul>
<li>Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions</li>
<li>Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁对冲基金级别的数据和强大的投资工具，帮助您做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，使您的投资组合始终处于最大潜力的状态</li>
</ul>
</div><p>CARsgen Therapeutics Holdings Ltd. ( (HK:2171) ) has issued an update.</p>
<div class="lb-trans"><p>CARsgen Therapeutics Holdings Ltd. ( (HK:2171) ) 发布了最新动态。</p>
</div><p>CARsgen Therapeutics has extended the term of its existing share repurchase plan to run until the conclusion of its next annual general meeting, after having already bought back 7,627,000 shares under its 2025 repurchase mandate. Funded by non-IPO sources such as business development and interest income, the move is framed by the board as a signal that the company’s share price undervalues its long-term growth prospects and as a measure to enhance shareholder value. Separately, substantial shareholder YIJIE Biotech Holding Limited and its concert parties have increased their stake to about 38.2% of issued shares (excluding treasury shares), a development the board interprets as further market confidence in CARsgen’s long-term investment appeal, albeit with the caveat that future buybacks remain discretionary and subject to market conditions.</p>
<div class="lb-trans"><p>CARsgen Therapeutics 已将现有股票回购计划的期限延长至下次年度股东大会结束，之前已根据 2025 年回购授权回购了 7,627,000 股。此次回购由非 IPO 来源（如业务发展和利息收入）资助，董事会将此举视为公司股价低估其长期增长前景的信号，并作为提升股东价值的措施。此外，主要股东 YIJIE Biotech Holding Limited 及其一致行动人已将其持股比例提高至约 38.2%（不包括库藏股），董事会将此发展解读为市场对 CARsgen 长期投资吸引力的进一步信心，尽管未来的回购仍然是自主决定，并受市场条件的影响。</p>
</div><p>The most recent analyst rating on (HK:2171) stock is a Sell with a HK$14.92 price target. To see the full list of analyst forecasts on CARsgen Therapeutics Holdings Ltd. stock, see the HK:2171 Stock Forecast page.</p>
<div class="lb-trans"><p>关于 (HK:2171) 股票的最新分析师评级为卖出，目标价为 HK$14.92。要查看 CARsgen Therapeutics Holdings Ltd. 股票的完整分析师预测列表，请参见 HK:2171 股票预测页面。</p>
</div><p><strong>More about CARsgen Therapeutics Holdings Ltd.</strong></p>
<div class="lb-trans"><p><strong>关于 CARsgen Therapeutics Holdings Ltd. 的更多信息</strong></p>
</div><p>CARsgen Therapeutics Holdings Limited is a biotechnology company focused on developing innovative cell therapies, particularly CAR-T treatments, for cancer. Listed on the Hong Kong Stock Exchange, the group operates through subsidiaries and affiliated entities, targeting both domestic and global oncology markets with advanced immunotherapy products.</p>
<div class="lb-trans"><p>CARsgen Therapeutics Holdings Limited 是一家生物技术公司，专注于开发创新的细胞疗法，特别是针对癌症的 CAR-T 治疗。该公司在香港证券交易所上市，通过子公司和关联实体运营，针对国内和全球肿瘤市场提供先进的免疫疗法产品。</p>
</div><p><strong>Average Trading Volume:</strong> 1,968,220</p>
<div class="lb-trans"><p><strong>平均交易量：</strong> 1,968,220</p>
</div><p><strong>Technical Sentiment Signal:</strong> Sell</p>
<div class="lb-trans"><p><strong>技术情绪信号：</strong> 卖出</p>
</div><p><strong>Current Market Cap:</strong> HK$8.6B</p>
<div class="lb-trans"><p><strong>当前市值：</strong> HK$8.6B</p>
</div><p>Find detailed analytics on 2171 stock on TipRanks’ Stock Analysis page.</p>
<div class="lb-trans"><p>在 TipRanks 的股票分析页面上查找关于 2171 股票的详细分析。</p>
</div>

科济药业-B 延长了股票回购计划，同时主要股东增加了持股比例